The ability of EVs to transfer TGFBR was observed in breast cancer, in which these cancer EVs transferred activated TGFBRs to CD8+ lymphocytes, exhausting them and transferring TGFBRs to MDA-MB-231 cells, promoting metastasis, paclitaxel, and DOX resistance (69). The gene discussed is CD8A; the disease is breast cancer.